1. < Cedars Sinai DoM

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

By sjmartinez • June 9, 2024

Nassar AH, Kim SY, Aredo JV, Feng J, Shepherd F, Xu C, Kaldas D, Gray JE, Dilling TJ, Neal JW, Wakelee HA, Liu Y, Lin SH, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron TU, Thummalapalli R, Yu H, Owen DH, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris JP, Nagasaka M, Ayanambakkam A, Velazquez AI, Ragavan M, Lin JJ, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar SR, Gupta S, Leal T, Kwiatkowski DJ, Mak RH, Adib E, Naqash AR, Goldberg SB. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. J Thorac Oncol. 2024 Jun;19(6):928-940. doi: 10.1016/j.jtho.2024.01.012. Epub 2024 Jan 24. PMID: 38278303.

Tags: Adverse events, Cedars Sinai DoM, chemotherapy, durvalumab, EGFR, Hematology/Oncology, Non–small cell lung cancer, Osimertinib, Publications, targeted therapy

Related Posts

Immunomodulatory Nanoparticles Enable Combination Therapies To Enhance Disease Prevention and Flare Control in Rheumatoid Arthritis

Johnson WT, Wilkinson EL, Iyer N, Dolmat M, Bollmann M, Dada N, Wei X, Yang S, Zhang T, Yoo G, Bernardo M, Price M, Frame[...]

All-in-One Cardiac MRI: Unified Non-Contrast-enhanced and Contrast-enhanced Imaging for a Continuous-Acquisition Examination

Mao X, Chen Z, Hu Z, Lee HL, Kwan AC, Cokic I, Cao T, Han F, Xie Y, Li D, Christodoulou AG. All-in-One Cardiac MRI:[...]

Minimum standards for training in colorectal endoscopic mucosal resection among advanced endoscopy trainees

Yang D, Robalino Gonzaga E, Hasan MK, Trindade AJ, Radlinski M, Burbridge RA, Mosko J, Taunk P, Jawaid S, Othman MO, Diehl DL, Khara HS,[...]